Rakuten Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Rakuten Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,201	Closed	-$603K	–	565
2025 Q4	$603K	Sell	4,201 -124,535	-97%	-$18M	﹤0.01%	563
2025 Q3	$8.62M	Buy	+128,736	New	+$17.4M	0.03%	160
2025 Q1	$316K	Buy	+2,794	New	+$354K	﹤0.01%	622
2024 Q3	$212K	Buy	1,841 +472	+34%	+$64.7K	﹤0.01%	488
2024 Q2	$184K	Buy	1,369 +519	+61%	+$71.2K	﹤0.01%	475
2024 Q1	$117K	Buy	850 +780	+1,114%	+$107K	﹤0.01%	471
2023 Q4	$9.25K	Buy	+70	New	+$8.06K	﹤0.01%	486

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rakuten Investment Management's NBIX Position: Q1 2026 in Review

Rakuten Investment Management sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 4,201 shares — an estimated $603K sold.

Rakuten Investment Management first reported a position in NBIX in Q4 2023 and held it in 7 quarters. The position peaked at $8.62M in Q3 2025. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Rakuten Investment Management reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
Rakuten Investment Management sold 4,201 Neurocrine Biosciences shares in Q1 2026, an estimated $603K.
Rakuten Investment Management first reported a position in Neurocrine Biosciences in Q4 2023 and held it in 7 quarters.
Rakuten Investment Management's Neurocrine Biosciences position peaked at $8.62M in Q3 2025.
695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Rakuten Investment Management's 13F filing for Q1 2026, filed 12 May 2026.